Jefferies lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $23 and keeps a Hold rating on the shares as the firm expects the deal to be acquired by Alkermes (ALKS) to close in Q1 of 2026 after Lundbeck decided not to raise its November 14 offer. The firm now thinks the chances of a competing bid are unlikely and lowered its target to reflect Alkermes’ November 18 offer to acquire Avadel for $22.50 per share, including $21 upfront and a $1.50 per share CVR.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals price target raised to $22.50 from $20 at Wells Fargo
- Avadel Pharmaceuticals Amends Agreement with Alkermes
- Alkermes increases offer to acquire Avadel Pharmaceuticals to $22.50 per share
- Avadel Pharmaceuticals put volume heavy and directionally bearish
- Avadel Pharmaceuticals Receives Superior Proposal from Lundbeck